Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday for rheumatoid arthritis.

The oral Janus kinase-1 (JAK-1) inhibitor is indicated to treat adults with moderate to severely active RA with inadequate response or intolerance to methotrexate. AbbVie Inc. (NYSE:ABBV) plans to launch the drug late this month at an annual wholesale acquisition cost (WAC) of $59,000. ...